Literature DB >> 7534597

Biochemical markers of basement membrane disturbances and occupational exposure to hydrocarbons and mixed solvents.

A Stevenson1, M Yaqoob, H Mason, P Pai, G M Bell.   

Abstract

To investigate possible mechanisms of hydrocarbon or solvent-induced renal damage, we studied three groups of healthy men employed in a UK manufacturing plant. Group 1 (n = 111) were occupationally exposed to hydrocarbon-based paints, Group 2 (n = 100) were occupationally exposed to petroleum-based mineral oils, and Group 3 (n = 92) had low background occupational exposure to hydrocarbons. Occupational atmospheric exposure levels for toluene, xylene, butanol and oil mist around the time of this study were within UK permissible limits. Group 4 (controls) were males with no known occupational hydrocarbon or solvent exposure (n = 108). Circulating laminin antibodies and the auto-antibody implicated in Goodpasture's syndrome (anti-GBM) were measured, as were serum laminin, a basement membrane turnover marker, and soluble E-selectin, an endothelial activation marker. Group 1 had a significantly greater proportion of subjects with high levels of both anti-laminin antibodies and soluble E-selectin; Group 2 had significantly more subjects with raised anti-GBM antibodies, laminin and soluble E-selectin. Mean levels of soluble E-selectin were increased in Groups 1 and 2. In a small but significant proportion of these workers exposed to hydrocarbons/mixed solvents there are alterations both to basement membranes, resulting in auto-antibody production, and to overlying vascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534597

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  9 in total

1.  Pulmonary hemorrhage complicating Goodpasture's disease in the course of pulmonary tuberculosis.

Authors:  Yao-Ko Wen; Kai-I Wen
Journal:  Int Urol Nephrol       Date:  2012-07-24       Impact factor: 2.370

2.  Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease.

Authors:  Stephen W Olson; Charles B Arbogast; Thomas P Baker; David Owshalimpur; David K Oliver; Kevin C Abbott; Christina M Yuan
Journal:  J Am Soc Nephrol       Date:  2011-08-25       Impact factor: 10.121

Review 3.  Advances in human antiglomerular basement membrane disease.

Authors:  Zhao Cui; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2011-07-19       Impact factor: 28.314

4.  Nephrotoxicity of organic solvents: biomarkers for early detection.

Authors:  Jens-Uwe Voss; Markus Roller; Elke Brinkmann; Inge Mangelsdorf
Journal:  Int Arch Occup Environ Health       Date:  2005-05-13       Impact factor: 3.015

Review 5.  Mammalian collagen IV.

Authors:  Jamshid Khoshnoodi; Vadim Pedchenko; Billy G Hudson
Journal:  Microsc Res Tech       Date:  2008-05       Impact factor: 2.769

6.  A role for collagen IV cross-links in conferring immune privilege to the Goodpasture autoantigen: structural basis for the crypticity of B cell epitopes.

Authors:  Roberto M Vanacore; Amy-Joan L Ham; Jean-Philippe Cartailler; Munirathinam Sundaramoorthy; Parvin Todd; Vadim Pedchenko; Yoshikazu Sado; Dorin-Bogdan Borza; Billy G Hudson
Journal:  J Biol Chem       Date:  2008-05-22       Impact factor: 5.157

7.  Air pollution in early life and adult mortality from chronic rheumatic heart disease.

Authors:  David I W Phillips; Clive Osmond; Martin L Williams; Alexander Jones
Journal:  Int J Epidemiol       Date:  2017-08-01       Impact factor: 7.196

8.  Isolated Pauci-Immune Pulmonary Capillaritis Associated with Hydrocarbon Inhalation and Marijuana Smoking: An Unusual Case of Severe Hypoxemia.

Authors:  Jason S Oh; Uni Wong; Divyansh Bajaj; Stella E Hines
Journal:  Case Rep Pulmonol       Date:  2020-01-19

9.  The clinical and immunological features of the post-extracorporeal shock wave lithotripsy anti-glomerular basement membrane disease.

Authors:  Beining Wang; Jia Xiaoyu; Xiaojuan Yu; Zhao Cui; Minghui Zhao
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.